Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Dec 26, 2018; 10(12): 183-195
Published online Dec 26, 2018. doi: 10.4252/wjsc.v10.i12.183
Cancer stem cell impact on clinical oncology
Mariel E Toledo-Guzmán, Gabriele D Bigoni-Ordóñez, Miguel Ibáñez Hernández, Elizabeth Ortiz-Sánchez
Mariel E Toledo-Guzmán, Gabriele D Bigoni-Ordóñez, Elizabeth Ortiz-Sánchez, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Mexico City 14080, Mexico
Mariel E Toledo-Guzmán, Miguel Ibáñez Hernández, Departamento de Bioquímica, Laboratorio de Terapia Génica, Escuela Nacional de Ciencias Biológicas, Posgrado de Biomedicina y Biotecnología Molecular, Instituto Politécnico Nacional, Mexico City 11340, Mexico
Author contributions: Toledo-Guzmán ME participated in the conception and writing of the manuscript; Bigoni-Ordóñez GD generated the figures; Ibáñez Hernández M reviewed and suggested modifications to the content; Ortiz-Sánchez E designed the aim of the editorial, participated in the conception and contributed to the writing of the manuscript.
Supported by Institutional funding at Instituto Nacional de Cancerología.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author to: Elizabeth Ortiz-Sánchez, MD, PhD, Academic Research, Professor, Research Scientist, Senior Researcher, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Av San Fernando 22, Colonia Sección XVI, Mexico City 14080, Mexico.
Telephone: +52-55-54280400
Received: September 13, 2018
Peer-review started: September 13, 2018
First decision: October 5, 2018
Revised: October 15, 2018
Accepted: November 15, 2018
Article in press: November 16, 2018
Published online: December 26, 2018
Core Tip

Core tip: Tumor heterogeneity can explain the presence of cells that display high tumorigenic capacity along with chemo- and radio-resistance properties. These cells, identified as cancer stem cells (CSCs), are partially responsible for recurrence and tumor progression. Most tumors follow the CSC model, which indicates the existence of a subset of highly tumorigenic cells. This has been shown to be the case for several patients with several types of tumors. In this review, we focus on the phenotypes used for the study and identification of CSCs from human samples, as well as promising strategies to target CSCs.